Cargando…

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion

Paclitaxel, a new antitubular agent, appears to be one of the most promising single agents for the chemotherapy of various solid tumors. The primary objectives of this phase I study of paclitaxel using 24‐h continuous intravenous infusions were to determine the maximum tolerated dose of paclitaxel a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Tomohide, Sasaki, Yasutsuna, Eguchi, Kenji, Shinkai, Tetsu, Ohe, Yuichiro, Nishio, Makoto, Kunikane, Hiroshi, Arioka, Hitoshi, Karato, Atsuya, Omatsu, Hironobu, Nakashima, Hajime, Saijo, Nagahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1994
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919347/ https://www.ncbi.nlm.nih.gov/pubmed/7961108 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02906.x

Ejemplares similares

A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin
por: Ohmatsu, Hironobu, et al.
Publicado: (1994)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer
por: Yamamoto, Nobuyuki, et al.
Publicado: (1994)

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging
por: Miya, Toshimichi, et al.
Publicado: (1992)

Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)
por: Sasaki, Yasutsuna, et al.
Publicado: (1990)

Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer
por: Eguchi, Kenji, et al.
Publicado: (1990)

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
por: Oshita, Fumihiro, et al.
Publicado: (1995)

Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
por: Shinkai, Tetsu, et al.
Publicado: (1989)

Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel
por: Minami, Hironobu, et al.
Publicado: (2001)

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
por: Sano, Tetsuro, et al.
Publicado: (1988)

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs
por: Ohtsu, Atsushi, et al.
Publicado: (1989)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.
por: Kunitoh, H., et al.
Publicado: (1998)

CORRECTION
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

Basic Design Considerations for Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1992)

Guidelines for Analysis and Reporting of Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1993)

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1997)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene
por: Kurokawa, Hirokazu, et al.
Publicado: (1997)

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)
por: Ohmori, Tohru, et al.
Publicado: (1993)

Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay
por: Oshita, Fumihiro, et al.
Publicado: (1995)

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells
por: Arioka, Hitoshi, et al.
Publicado: (1999)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis
por: Fukuda, Minoru, et al.
Publicado: (1996)

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin
por: Naruse, Ichiro, et al.
Publicado: (2002)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f
por: Nomoto, Taisuke, et al.
Publicado: (1998)

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP
por: Nishio, Kazuto, et al.
Publicado: (1992)

p16(INK4) Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors
por: Fukuoka, Kazuya, et al.
Publicado: (1997)

First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial
por: Kim, Hye Ryun, et al.
Publicado: (2023)

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study
por: Doz, F, et al.
Publicado: (2001)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Present Status and Problems on Molecular Targeted Therapy of Cancer
por: Saijo, Nagahiro
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0f88i4egj9e6t6c6vjnldlg4f4